Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
Find the perfect cards to make your season’s greetings go even further. Every pack purchased will help fund vital research and support for people living with type 1 diabetes.
Researchers need your help. By taking part in research studies and clinical trials, you will help them make progress to improve lives and find a cure for type 1 diabetes.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Your donation helps support people living with type 1 diabetes and funds the best treatment and cure research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > About Breakthrough T1D UK & our impact > Our research > Research projects > Engineering a device to measure how much insulin someone is making
Dr Samet Sahin is part of an engineering research group at the University of Lancaster and is applying his knowledge in engineering to tackle a problem in type 1 diabetes (T1D). In his project funded by Breakthrough T1D, Samet will develop a quick and easy tool to allow healthcare professionals to measure how much insulin a person can make.
Beta cells release a molecule called C-peptide (short for connecting peptide) with insulin in equal amounts. C-peptide stays in the body longer than insulin before it breaks down and is used to calculate how much insulin beta cells are releasing. This measurement can be used to understand how many functioning beta cells a person with T1D still has.
C-peptide is currently measured using a blood test, which is then sent to a lab for analysis. This process is time-consuming and expensive making it impractical for both healthcare professionals and their patients. Samet is tackling this issue by developing a tool for healthcare professionals to quickly, easily, and reliably measure an individual’s C-peptide levels.
Samet is making an electrochemical sensor that uses a sophisticated combination of chemistry and electricity to detect C-peptide levels in blood samples. The sensor would enable patients to do a simple finger prick test while at their GP or in a diabetes clinic that the sensor would use to give a measurement of C-peptide in minutes without the need for lab tests. Samet’s sensor promises to offer a significant reduction in time and practicality compared to current methods.
Measuring beta cell function is crucial to understand how an individual’s T1D is progressing. T1D develops in stages as more and more beta cells are destroyed. People in the early stages don’t require insulin, but they will do when they reach stage three.
Being able to quickly and easily assess someone’s beta cell function will help clinicians monitor people in the early stages of T1D to ensure they start insulin therapy at the right time. This timely care would help to avoid the long- and short-term consequences of a late diagnosis in diabetic ketoacidosis (DKA).
Treatments to protect beta cells are emerging, including immunotherapies like teplizumab (licensed in the US) and drugs repurposed from other conditions. Samet’s sensor could be used to measure how well these therapies are working to delay the onset of T1D in clinical trials and even one day in clinic. This new monitoring technique could unlock the potential for personalised care in T1D treatment, as an individual could try different therapies and use the sensor in clinic to find what works best for them.
As well as helping us monitor how T1D is progressing and whether immunotherapies are working, C-peptide tests could help identify misdiagnoses between type 1 and type 2 diabetes. We recently funded Dr Nicholas Thomas’ project at the University of Exeter to explore whether measuring the C-peptide levels in people three years after starting insulin therapy can accurately diagnose either type 1 or type 2 diabetes.
Dr Christiana Lekka, of the University of Exeter, is studying how type 1 diabetes (T1D) may affect the overall structure of the pancreas. The end goal of her research is to better understand how T1D can affect the entire organ, rather than just the insulin-producing cells (beta cells).
Dr. Ali Shilleh, Postdoctoral Research Fellow at the University of Oxford, is studying how cell signals are organised inside lab-grown insulin-producing cells. Understanding these signals could help scientists improve future cell replacement therapies for people with type 1 diabetes (T1D).
Dr Rachel Sumner and her team at the University of Bristol are investigating diabetes burnout, and how better to understand it. Diabetes burnout affects around one third of people with type 1 diabetes (T1D), and although known about, it is poorly understood. The researchers aim to find investigate the biological and psychosocial impacts of diabetes burnout, to further help future studies.
Dr Rachael Hughson-Gill is a researcher at the University of Lincoln, who is studying how body image issues affect young women with type 1 diabetes (T1D).
Would you like to visit the website of our {{ affiliate_country }} affiliate to complete your action?